Newer antihypertensive drug therapies

Are they better for pulmonary patients?

Research output: Contribution to journalArticle

Abstract

Diuretics are a mainstay of antihypertensive therapy for patients with asthma or chronic obstructive pulmonary disease (COPD); ability to clear airway secretions and, in patients with COPD, electrolyte and acid-base status should be monitored. β-Blockers are contraindicated in asthma and are generally better avoided in COPD; if benefit outweighs risk (as it may in cases of acute myocardial infarction, for example), start with a trial of a low dose of a β 1-selective agent without intrinsic sympathomimetic activity. α-Blockers and calcium channel blockers have favorable safety profiles with concomitant pulmonary disease; monitor oxygenation and right ventricular function in COPD patients receiving calcium channel blockers. Medications that exert inhibitory effects on the renin-angiotensin-aldosterone system may also have bronchoprotective effects. The new angiotensin II receptor blockers are an option for patients who cannot tolerate angiotensin-converting enzyme inhibitors.

Original languageEnglish
Pages (from-to)437-446
Number of pages10
JournalThe Journal of critical illness
Volume15
Issue number8
StatePublished - 2000

Fingerprint

Chronic Obstructive Pulmonary Disease
Antihypertensive Agents
Drug Therapy
Lung
Calcium Channel Blockers
Asthma
Right Ventricular Function
Sympathomimetics
Angiotensin Receptor Antagonists
Renin-Angiotensin System
Angiotensin-Converting Enzyme Inhibitors
Diuretics
Electrolytes
Lung Diseases
Myocardial Infarction
Safety
Acids
Therapeutics

All Science Journal Classification (ASJC) codes

  • Critical Care and Intensive Care Medicine

Cite this

Newer antihypertensive drug therapies : Are they better for pulmonary patients? / Nair, C. K.; Faulkner, Michele A.

In: The Journal of critical illness, Vol. 15, No. 8, 2000, p. 437-446.

Research output: Contribution to journalArticle

@article{96143e4144dc4d03a3bc522d73ec686c,
title = "Newer antihypertensive drug therapies: Are they better for pulmonary patients?",
abstract = "Diuretics are a mainstay of antihypertensive therapy for patients with asthma or chronic obstructive pulmonary disease (COPD); ability to clear airway secretions and, in patients with COPD, electrolyte and acid-base status should be monitored. β-Blockers are contraindicated in asthma and are generally better avoided in COPD; if benefit outweighs risk (as it may in cases of acute myocardial infarction, for example), start with a trial of a low dose of a β 1-selective agent without intrinsic sympathomimetic activity. α-Blockers and calcium channel blockers have favorable safety profiles with concomitant pulmonary disease; monitor oxygenation and right ventricular function in COPD patients receiving calcium channel blockers. Medications that exert inhibitory effects on the renin-angiotensin-aldosterone system may also have bronchoprotective effects. The new angiotensin II receptor blockers are an option for patients who cannot tolerate angiotensin-converting enzyme inhibitors.",
author = "Nair, {C. K.} and Faulkner, {Michele A.}",
year = "2000",
language = "English",
volume = "15",
pages = "437--446",
journal = "Journal of Critical Illness",
issn = "1040-0257",
publisher = "Cliggott Publishing Co.",
number = "8",

}

TY - JOUR

T1 - Newer antihypertensive drug therapies

T2 - Are they better for pulmonary patients?

AU - Nair, C. K.

AU - Faulkner, Michele A.

PY - 2000

Y1 - 2000

N2 - Diuretics are a mainstay of antihypertensive therapy for patients with asthma or chronic obstructive pulmonary disease (COPD); ability to clear airway secretions and, in patients with COPD, electrolyte and acid-base status should be monitored. β-Blockers are contraindicated in asthma and are generally better avoided in COPD; if benefit outweighs risk (as it may in cases of acute myocardial infarction, for example), start with a trial of a low dose of a β 1-selective agent without intrinsic sympathomimetic activity. α-Blockers and calcium channel blockers have favorable safety profiles with concomitant pulmonary disease; monitor oxygenation and right ventricular function in COPD patients receiving calcium channel blockers. Medications that exert inhibitory effects on the renin-angiotensin-aldosterone system may also have bronchoprotective effects. The new angiotensin II receptor blockers are an option for patients who cannot tolerate angiotensin-converting enzyme inhibitors.

AB - Diuretics are a mainstay of antihypertensive therapy for patients with asthma or chronic obstructive pulmonary disease (COPD); ability to clear airway secretions and, in patients with COPD, electrolyte and acid-base status should be monitored. β-Blockers are contraindicated in asthma and are generally better avoided in COPD; if benefit outweighs risk (as it may in cases of acute myocardial infarction, for example), start with a trial of a low dose of a β 1-selective agent without intrinsic sympathomimetic activity. α-Blockers and calcium channel blockers have favorable safety profiles with concomitant pulmonary disease; monitor oxygenation and right ventricular function in COPD patients receiving calcium channel blockers. Medications that exert inhibitory effects on the renin-angiotensin-aldosterone system may also have bronchoprotective effects. The new angiotensin II receptor blockers are an option for patients who cannot tolerate angiotensin-converting enzyme inhibitors.

UR - http://www.scopus.com/inward/record.url?scp=0033847969&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0033847969&partnerID=8YFLogxK

M3 - Article

VL - 15

SP - 437

EP - 446

JO - Journal of Critical Illness

JF - Journal of Critical Illness

SN - 1040-0257

IS - 8

ER -